ArticleDrug metabolism and disposition: the biological fate of chemicals2010
Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.Clinical pharmacology and therapeutics · 2017Guideline
- Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method.British journal of clinical pharmacology · 2026Trial
- Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.Clinical and translational science · 2019Trial
- Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.British journal of clinical pharmacology · 2018Trial
- Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.The Journal of pediatrics · 2018Trial
- Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Genetic testing and molecular biomarkers · 2016Trial
- Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.The Journal of pediatrics · 2013Trial
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.European journal of clinical pharmacology · 2012Trial
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population.CPT: pharmacometrics & systems pharmacology · 2024Article
- Article
- PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.Archives of pharmacal research · 2024Article
- Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives.Paediatric drugs · 2023Review
- Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.Pediatric research · 2022Review
- Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Digestive diseases and sciences · 2021Review
- Gene-Based Dose Optimization in Children.Annual review of pharmacology and toxicology · 2020Review
- Article
- Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.Contemporary clinical trials · 2019Article
- Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.Molecular medicine reports · 2018Article
- Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.European journal of pediatrics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The impact of the CYP2C19*17 allele on the pharmacokinetics of pantoprazole and omeprazole in previously studied children (n = 40) was explored. When pantoprazole area under the plasma concentration versus time curve (AUC) was examined as a function of CYP2C19 genotype, a significantly lower AUC was observed for subjects identified as CYP2C19*1/*1 and *1/*17. For pantoprazole, a statistically significant relationship was observed between CYP2C19 genotype and both dose-corrected AUC (p < 0.0001) and the apparent elimination rate constant (K(el); p = 0.0012); no significant genotype-phenotype relationships were observed for omeprazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.